Home About Us Government Relations and Advocacy Media Contact Us Site Map Privacy Français  
Multiple Sclerosis Society of CanadaSociété canadienne de la sclérose en plaques
Multiple Sclerosis Living with Multiple Sclerosis Research Treatments Donate Now Get Involved Special Events

 


Treatments
    share +

Your Options
line

There are currently ten disease-modifying therapies approved by Health Canada.

In large clinical trials, all of these drugs have been found to have a direct influence on altering the course of MS. They are sometimes referred to collectively as disease-modifying therapies.

None of these treatments are a cure, and none will prevent recurring symptoms, such as fatigue or numbness. However each of them has a proven record of effectiveness. Unfortunately, no disease-modifying therapy has yet been approved to treat primary progressive MS — the type of MS that shows steady progression at onset.

The cost of disease-modifying therapies for MS varies widely, from about $20,000 to $40,000 per year. The actual cost will depend on the treatment selected, the dosage, provincial pricing, pharmacy or clinic costs, dispensing fees, etc.

The MS Society is aware that the level of reimbursement and access criteria vary from province to province and is working to ensure that people who could benefit from treatment have access.

For more information about these therapies or for other information about MS management, please contact your physician, or the nearest Multiple Sclerosis Society of Canada division office at 1-800-268-7582.

» Drug Information


Brand
(Generic Name)
Frequency Route of Delivery Usual Dose
Aubagio®
(teriflunomide)
Every day Capsule taken orally 14 mg
Avonex®
(interferon beta-1a)
Once a week Intramuscular (into the muscle) injection 30 mcg
Betaseron® (interferon beta-1b) Every other day subcutaneous (under the skin) injection 250 mcg
Copaxone® (glatiramer acetate) Every day subcutaneous (under the skin) injection 20 mg (20,000 mcg)
Extavia®
(interferon beta-1b)
Every other day subcutaneous (under the skin) injection 250 mcg
Gilenya
(fingolimod)
Every day Capsule taken orally 0.5 mg
Rebif®
(interferon beta-1a)
Three times a week subcutaneous (under the skin) injection 44 mcg
Tecfidera
(dimethyl fumarate)
Twice daily Two 120mg capsules taken orally, twice daily

One 240mg capsule taken orally, twice daily
480 mg
Tysabri® (natalizumab) Every four weeks IV infusion in a registered infusion facility 300 mg

Manufacturer/Distributor & Year of Health Canada Approval

Aubagio® Genzyme, a Sanofi company — 2013
Avonex® Biogen Idec Canada — 1998
Betaseron® Bayer HealthCare Pharmaceuticals, Inc. — 1995
Copaxone® Teva Neuroscience — 1997
Extavia® Novartis Pharmaceuticals Canada Inc. — 2009
Gilenya® Novartis Pharmaceuticals Canada Inc. — 2011
Rebif® EMD Serono Canada Inc. — 1998
Tecfidera Biogen Idec Canada Inc. — 2013
Tysabri® Biogen Idec Canada Inc. — 2006

» Industry-Sponsored Sites


Aubagio®
MS One to One®
1-855-MS1-2ONE
(1-855-671-2669)
Gilenya®
Gilenya Go Program®
www.gilenya.ca
1-855-PILL-4MS
(1-855-745-5467)
Betaseron®
BETAPLUS®
www.betaplus.ca
1-800-977-2770
Copaxone®
Shared Solutions®
www.mswatch.ca
1-800-283-0034
Avonex®
Tysabri®
Tecfidera
Biogen Idec ONEProgram
1-855-MSONE-00
(1-855-676-6300)
Rebif®
Multiple Support Program®
www.msprogram.ca
1-877-677-3243
Extavia®
Extracare®
www.extavia.ca
1-888-557-5050

Back to top

line

The drug information contained in this publication has been obtained from the manufacturers’ product monographs. Consult the package insert for more detailed information about the product’s indications, contraindications, medical use and side effects. If you are taking any of the medications listed above, do not change the dose or stop taking your medication without consulting your physician first.

Aubagio® is a registered trademark of Genzyme, a Sanofi company
Avonex® is a registered trademark of Biogen Idec Canada Inc.
Betaplus® is a registered trademark of Bayer HealthCare Pharmaceuticals
Betaseron® is a registered trademark of Bayer HealthCare Pharmaceuticals
Biogen Idec ONE™ Program is a registered trademark of Biogen Idec Canada Inc.
Copaxone® is a registered trademark of Teva Neuroscience
Extavia® is a registered trademark of Novartis Pharmaceuticals Canada Inc.
Gilenya® is a registered trademark of Novartis Pharmaceuticals Canada Inc.
Gilenya GO Program® is a registered trademark of Novartis Pharmaceuticals Canada Inc.
Rebif® is a registered trademark of EMD Serono Canada Inc.
MS One to One® is a registered trademark of Genzyme, a Sanofi company
Multiple Support Program® is a registered trademark of EMD Serono Canada Inc.
Shared Solutions® is a registered trademark of Teva Neuroscience
Tecfidera™ is a registered trademark of Biogen Idec Canada Inc.
Tysabri® is a registered trademark of Biogen Idec Canada Inc. and Elan Pharmaceuticals


© 2010, National Multiple Sclerosis Society (updated 2013)

This resource has been adapted by the Multiple Sclerosis Society of Canada with permission of the National Multiple Sclerosis Society (USA).

Back to top

line
Charitable registration
10774 6174 RR0001
Multiple Sclerosis Society of Canada
Toll free to reach the nearest regional office: 1 800 268-7582

To locate the MS Society office near you, please select your region:

E-mail: info@mssociety.ca
(Please provide your town and province in your e-mail)

Multiple Sclerosis   Living with MS   Research   Treatments   Donate Now   Get Involved    Special Events

Home    About Us    Advocacy    Media    Contact Us    Site Map    Privacy    Français